<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recommended intravenous doses of antimicrobial therapy for adults with bacterial brain abscess who have normal renal and hepatic function</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recommended intravenous doses of antimicrobial therapy for adults with bacterial brain abscess who have normal renal and hepatic function</h1>
<div class="graphic"><div class="figure"><div class="ttl">Recommended intravenous doses of antimicrobial therapy for adults with bacterial brain abscess who have normal renal and hepatic function</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Antimicrobial agent</td> <td class="subtitle1">Dose (adult)</td> <td class="subtitle1">Comment</td> </tr> <tr> <td>Amikacin</td> <td>5 mg/kg every 8 hours*</td> <td>Aminoglycosides are not routinely used for treatment of brain abscess, but may be considered in select cases (eg, multidrug-resistant gram-negative infection when treatment options are limited).</td> </tr> <tr> <td>Ampicillin</td> <td>2 g every 4 hours</td> <td> </td> </tr> <tr> <td>Aztreonam</td> <td>2 g every 6 to 8 hours</td> <td>Alternative agent generally used for patients with severe beta-lactam allergies.</td> </tr> <tr> <td>Cefepime</td> <td>2 g every 8 hours</td> <td> </td> </tr> <tr> <td>Cefotaxime</td> <td>2 g every 4 to 6 hours</td> <td> </td> </tr> <tr> <td>Ceftaroline</td> <td>600 mg every 8 hours</td> <td>Alternative therapy in cases of MRSA that are not responding to vancomycin or linezolid; if used, many experts would combine with another agent effective against MRSA.</td> </tr> <tr> <td>Ceftazidime</td> <td>2 g every 8 hours</td> <td> </td> </tr> <tr> <td>Ceftriaxone</td> <td>2 g every 12 hours</td> <td> </td> </tr> <tr> <td>Ciprofloxacin</td> <td>400 mg every 8 to 12 hours</td> <td>Alternative agent generally used for patients with severe beta-lactam allergies.</td> </tr> <tr> <td>Daptomycin</td> <td>6 to 10 mg/kg every 24 hours</td> <td> <p>Alternative agent for suspected <em>S. aureus</em> (or proven MRSA) in patients who cannot tolerate vancomycin.</p> Daptomycin has poor central nervous system penetration and is generally not recommended; if used because other alternatives are not available, it should be combined with rifampin therapy.</td> </tr> <tr> <td>Gentamicin</td> <td>1.7 mg/kg every 8 hours*</td> <td>Aminoglycosides are not routinely used for treatment of brain abscess, but may be considered in select cases (eg, multidrug-resistant gram-negative infection when treatment options are limited).</td> </tr> <tr> <td>Linezolid<sup>¶</sup></td> <td>600 mg every 12 hours</td> <td>Alternative agent for suspected <em>S. aureus</em> (or proven MRSA) in patients who cannot tolerate vancomycin.</td> </tr> <tr> <td>Meropenem</td> <td>2 g every 8 hours</td> <td> </td> </tr> <tr> <td>Metronidazole</td> <td>7.5 mg/kg (usually 500 mg) every 6 to 8 hours; maximum dose: 4 g/day</td> <td> </td> </tr> <tr> <td>Moxifloxacin</td> <td>400 mg every 24 hours</td> <td>Alternative agent generally used for patients with severe beta-lactam allergies.</td> </tr> <tr> <td>Nafcillin</td> <td>2 g every 4 hours</td> <td> </td> </tr> <tr> <td>Oxacillin</td> <td>2 g every 4 hours</td> <td> </td> </tr> <tr> <td>Penicillin G potassium</td> <td>4 million units every 4 hours</td> <td> </td> </tr> <tr> <td>Rifampin</td> <td>600 mg every 24 hours<sup>Δ</sup></td> <td>Rifampin should not be used as monotherapy, but it may be used in combination with other agents to enhance the antimicrobial activity.</td> </tr> <tr> <td>Tobramycin</td> <td>1.7 mg/kg every 8 hours*</td> <td>Aminoglycosides are not routinely used for treatment of brain abscess but may be considered in select cases (eg, multidrug-resistant gram-negative infection when treatment options are limited).</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole (co-trimoxazole)</td> <td>5 mg/kg every 8 to 12 hours<sup>◊</sup></td> <td> </td> </tr> <tr> <td>Vancomycin</td> <td>15 to 20 mg/kg every 8 to 12 hours<sup>§</sup></td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes">MRSA: methicillin-resistant <em>Staphylococcus</em> aureus; IV: intravenously; AUC: area under the curve.<br/>
	
	* The doses are based on ideal body weight or adjusted body weight except in underweight patients. A calculator for ideal body weight and adjusted body weight is available in UpToDate. For gentamicin or tobramycin, dose and interval must be individualized to produce a peak serum concentration of 7 to 10 mcg/mL and trough serum concentration &lt;2 mcg/mL (ideally &lt;1 mcg/mL); for amikacin, target a peak serum concentration of 25 to 40 mcg/mL and trough serum concentration of &lt;8 mcg/mL (ideally &lt;4 mcg/mL). There are insufficient data to suggest dosing using a high-dose extended-interval regimen. On rare occasion (eg, if the abscess has ruptured into the ventricles), intrathecal administration may be warranted. For additional information, refer to the UpToDate topic on aminoglycoside dosing and administration.<br/>
	
	¶ Prolonged therapy with linezolid increases the risk of serious toxicity (eg, hematologic toxicity typically occurs when used longer than two weeks). Linezolid may be administered orally instead of IV in select settings (eg, those with poor IV access who have had an appropriate initial response).<br/>
	
	Δ Rifampin can be administered orally instead of IV.<br/>
<span class="lozenge">◊</span> Dosage is based on the trimethoprim component. We administer trimethoprim-sulfamethoxazole at a dose of 5 mg/kg (based on the trimethoprim component) IV every 8 hours in patients with normal renal function. However, there are limited data on the preferred dosing interval; in case reports, dosing intervals of every 6 hours or every 12 hours were also used.<br/>
	
	§ For treatment of brain abscess due to known or suspected <em>S. aureus</em>, a vancomycin loading dose (20 to 35 mg/kg) is appropriate;<sup>[1,2]</sup> within this range, we use a higher dose for critically ill patients. The loading dose is based on actual body weight, rounded to the nearest 250 mg increment (maximum dose: 3 g). The initial maintenance dose and interval may be determined either by nomogram (typically 15 to 20 mg/kg every 8 to 12 hours [maximum single dose: 2 g; maximum daily dose: 4.5 g] for most patients with normal renal function) or by utilizing first-order equations based on estimates of creatinine clearance using the Cockcroft-Gault equation. Subsequent dose and interval adjustments are based on AUC-guided or trough-guided serum concentration monitoring. For treatment of brain abscess due to pathogens other than <em>S. aureus</em>, a loading dose is generally not required. Refer to the UpToDate topic on vancomycin dosing for additional information, including a sample nomogram and discussion of vancomycin monitoring.</div><div class="graphic_reference">References:
	<ol>
<li>Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary. Clin Infect Dis 2011; 52:285.</li>
<li>Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus Aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</li>
</ol></div><div id="graphicVersion">Graphic 134360 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
